First-line Treatment of Non-Small Cell Lung Cancer Under Routine Conditions: Observational Study on Overall Survival
N/A
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Non Small Cell Lung Cancer
Both
Non Small Cell Lung Cancer
Trial Information
First-line Treatment of Non-Small Cell Lung Cancer Under Routine Conditions: Observational Study on Overall Survival
Inclusion Criteria:
- Histological or cytological diagnosis of non-small cell lung cancer (NSCLC) stage
IIIB-IV
- Initiation of first-line treatment for advanced NSCLC with any platinum-based doublet
chemotherapy, with or without additional targeted agents
- 18 years of age or older
Exclusion Criteria:
- Participating simultaneously in a study including administration of any
investigational drug or procedure at entry into this study
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
Overall survival
Outcome Time Frame:
Treatment start to death from any cause (follow-up assessments until death or until end of study, up to 18 months from Last Patient Entered Treatment)
Safety Issue:
No
Principal Investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Investigator Role:
Study Director
Investigator Affiliation:
Eli Lilly and Company
Authority:
Finland: Ethics Committee
Study ID:
13095
NCT ID:
NCT01067794
Start Date:
April 2009
Completion Date:
July 2012
Related Keywords:
- Non Small Cell Lung Cancer
- Metastatic
- Advanced
- Stage IIIB-IV
- daily
- hospital
- practice
- setting
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|---|
